Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Directorate Change

5 Dec 2023 07:00

RNS Number : 6219V
Surgical Innovations Group PLC
05 December 2023
 

Surgical Innovations Group Plc

 ("Surgical Innovations", the "Company" or the "Group")

 

 

Directorate Change

 

Surgical Innovations appoints Keyvan Djamarani as Independent Non-executive Director

Nigel Rogers steps down, concluding the Board succession plan

 

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces that Keyvan Djamarani has been appointed as Independent Non-executive Director with immediate effect. This follows an extensive process led by an independent head-hunter. At the same time Nigel Rogers, who previously served time as Chair of the Company, will step down from the Board.

 

Keyvan has over 30 years' relevant experience, holding numerous leadership roles in product development within manufacturing organisations covering medical and pharmaceutical drug delivery devices. He has a track record of delivering increased sales, profitability and business critical programmes and projects. Most recently he spent over nine years as Managing Director/Business President at Bespak Europe, a medical and pharmaceutical drug delivery devices business. Keyvan began his career at Unilever working in their Detergents and Personal Products Divisions prior to joining Bespak. At Bespak, Keyvan held several roles across their European and North American divisions. Within this period, from 2002 to 2005, Keyvan was General Manager and President of Bespak Inc. and from 2010 to 2013, Keyvan became CEO of King Systems, an airways management business, encompassing design, development and manufacture of airway management products. Keyvan was most recently a Non-executive Director of CEME Ltd, a not-for-profit business enterprise operating on a 19-acre campus, home to over 100 engineering, technology and training businesses - a role he held for over 16 years.

 

As announced on 22 May 2023, Nigel Rogers will step down from the Board with immediate effect, concluding the final part of the planned Board succession process. Nigel joined the Board in 2015, bringing stability to the Company at a critical time. 

 

Chair of the Company, Jonathan Glenn, commented: "I would like to thank Nigel for the dedicated service he provided to Surgical Innovations over his eight-year tenure, bringing the Company safely through a number of significant challenges including the pandemic. His experience proved invaluable and his insight has always been appreciated by the Board and management.

"I am also delighted to welcome Keyvan to the Board. He has an excellent track record in the medical device sector and brings with him a broad and relevant skillset. His extensive operational experience will provide a wealth of expertise to the Board, affording valuable insight into the challenges of manufacturing as the Company undertakes a major efficiency drive to improve margins."

 

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Dr Keyvan Mehdi Djamarani (aged 62) is currently, or has during the past five years, been a director of the following companies:

 

Current directorships or partnerships

Previous directorships or partnerships

· n/a

· Centre for Engineering and Manufacturing Excellence Ltd

· Bespak Europe Limited

· Integrated Aluminium Components Limited

· The Medical House Group Limited

· The Medical House Limited

· The Medical House Products Limited

· Medical House (ASI) Limited

· Hyperlyser Limited

 

Save as set out in this announcement there are no further details to be disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rule for Companies.

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, CFO

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Oliver Platts

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / 07584 391 303

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

 

To receive regular updates by email, please contact si@walbrookpr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUPGUUPUPWGMC
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Apr 20267:00 amRNSFinal Results
9th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Jan 20267:00 amRNSChief Financial Officer update
18th Dec 20257:00 amRNSTrading Update
28th Nov 20257:00 amRNSNew LTIP & Grant of Options
29th Sep 20257:05 amRNSBoard Changes
29th Sep 20257:00 amRNSHalf-year Report
17th Sep 20253:15 pmRNSNotice of Results
27th Jun 20254:42 pmRNSResult of AGM
26th Jun 202511:36 amRNSWithdrawal of AGM Resolutions 9 and 10
4th Jun 20258:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
30th May 20257:00 amRNSFinal Results
10th Apr 20257:00 amRNSTrading update
1st Apr 202511:30 amRNSUpdate on timing of 2024 Full Year results
19th Feb 202510:11 amRNSHolding(s) in Company
17th Feb 20254:12 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSFY24 Trading Update & & Directorship Change
30th Sep 20247:00 amRNSHalf-year Report
10th Sep 20247:00 amRNSNotice of Results
27th Aug 20243:51 pmRNSHolding(s) in Company
27th Aug 20243:49 pmRNSHolding(s) in Company
19th Aug 20241:06 pmRNSHolding(s) in Company
19th Aug 20241:01 pmRNSHolding(s) in Company
29th Jul 202412:18 pmRNSHolding(s) in Company
25th Jul 20244:04 pmRNSHolding(s) in Company
17th Jun 20244:43 pmRNSResult of AGM
10th Jun 20247:00 amRNSDirectorate Change - Appointment of CFO
23rd May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd Apr 20243:34 pmRNSHolding(s) in Company
19th Apr 20246:25 pmRNSHolding(s) in Company
18th Apr 20247:01 amRNSFinal Results
18th Apr 20247:00 amRNSNew exclusive UK distribution agreements secured
9th Apr 20247:00 amRNSDirectorate Change & Notice of Results
29th Jan 20247:00 amRNSYear-end 2023 Trading Update
19th Dec 20237:00 amRNSDirectorate Change
5th Dec 20237:00 amRNSDirectorate Change
19th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTrading Update and Notice of Results
27th Jun 202312:12 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
26th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
25th May 202311:11 amRNSDirector/PDMR Shareholding - Replacement
25th May 20237:00 amRNSDirector/PDMR Shareholding
22nd May 20237:00 amRNSDirectorate changes and board succession planning
29th Mar 20237:00 amRNSFinal Results
3rd Mar 20237:00 amRNSNotice of Results and Investor Presentation
23rd Jan 20237:00 amRNSYear-end Trading Update
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.